Messenger Ribonucleic Acid (mRNA) Capping Enzyme Market Report 2025

The messenger ribonucleic acid (mRNA) capping enzyme market size has grown rapidly in recent years. It will grow from $0.89 billion in 2024 to $1.02 billion in 2025 at a compound annual growth rate (CAGR) of 14.6%. Growth in the historic period was driven by the expansion of molecular biology and biotechnology research, advances in genetic engineering and synthetic biology, increasing applications in vaccine research, rising government and private funding for RNA research, and growth in biopharmaceutical manufacturing.

The messenger ribonucleic acid (mRNA) capping enzyme market size is expected to see rapid growth in the next few years. It will grow to $1.73 billion in 2029 at a compound annual growth rate (CAGR) of 14.2%. Growth in the forecast period is expected to be supported by rising investment in RNA-based drug development, an expanding pipeline of mRNA-based clinical trials, growth in personalized and precision medicine, increasing focus on mRNA stability and translational efficiency, and wider adoption of mRNA vaccines and therapeutics. Key trends anticipated for the forecast period include integration with artificial intelligence and machine learning, development of in-vitro transcription (IVT) technologies, next-generation enzymatic capping systems, advancements in synthetic cap analogs and co-transcriptional capping technologies, and innovation in enzyme design.

The increasing adoption of personalized medicine is expected to support the growth of the messenger ribonucleic acid capping enzyme market in the coming years. Personalized medicine is a medical approach that tailors treatment based on an individual’s genetic profile, lifestyle, and environmental factors. This approach is gaining popularity due to progress in genetic testing technologies, which allow for more precise identification of patient-specific treatment needs, leading to more effective therapeutic outcomes. Messenger ribonucleic acid capping enzymes contribute to personalized medicine by enhancing the stability and functionality of therapeutic messenger ribonucleic acid, ensuring efficient translation into proteins designed to meet individual treatment requirements. For example, in February 2024, the Personalized Medicine Coalition, a non-profit organization based in the United States, reported that the Food and Drug Administration approved sixteen new personalized treatments for rare disease patients in 2023, a notable increase from six approvals in 2022. Therefore, the growing adoption of personalized medicine is contributing to the expansion of the messenger ribonucleic acid capping enzyme market.

Leading companies in the messenger ribonucleic acid capping enzyme market are introducing advanced solutions, such as broad temperature capping technologies, to simplify production and storage by reducing reliance on controlled temperature logistics. These broad temperature solutions are designed to maintain enzyme stability and performance across a wide range of temperatures, making them suitable for diverse production and storage conditions. For instance, in August 2022, New England Biolabs, a life sciences company based in the United States, introduced the Faustovirus Capping Enzyme, a novel enzymatic tool that addresses limitations in traditional messenger ribonucleic acid capping methods. This enzyme contains a single subunit with RNA triphosphatase, guanylyltransferase, and N7-guanine methyltransferase activities, and functions effectively within a temperature range of twenty to fifty-five degrees Celsius. It enables the synthesis of Cap-0 structures and can be used with an additional enzyme to generate Cap-1 structures through a single-pot reaction. This innovation integrates seamlessly into current production processes, offering improved capping efficiency, reducing enzyme consumption by up to fifty percent, and eliminating the need for hazardous solvents.

In February 2025, TriLink BioTechnologies, a biotechnology company based in the United States, formed a partnership with Aldevron to incorporate CleanCap messenger ribonucleic acid capping technology into Aldevron’s development and manufacturing services. The collaboration aims to improve messenger ribonucleic acid yield, streamline processing, and deliver higher-quality therapeutics using TriLink’s CleanCap analogs, which include CleanCap M6, AG three prime OMe, AG, and AU. These analogs provide over ninety-five percent capping efficiency and enhance expression levels. Aldevron is a contract development and manufacturing organization based in the United States.

Major players in the messenger ribonucleic acid (mRNA) capping enzyme market are Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Takara Bio Inc., Aldevron, New England Biolabs Inc., CellScript Inc., Krishgen Biosystems, Yeasen Biotechnology Co. Ltd., Novoprotein Scientific Inc., TriLink Biotechnologies LLC, Jena Bioscience GmbH, OZ Biosciences, SBS Biotech Ltd., Vazyme Biotech Co. Ltd., Enzynomics Inc., Creative Enzymes, Canvax Biotech SL, APExBIO Technology LLC, BOC Sciences, KACTUS Biosystems.

North America was the largest region in the messenger ribonucleic acid (mRNA) capping enzyme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in messenger ribonucleic acid (mRNA) capping enzyme report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the messenger ribonucleic acid (mRNA) capping enzyme market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Messenger ribonucleic acid (mRNA) capping enzyme is a crucial enzyme that modifies newly synthesized mRNA molecules in eukaryotic cells. It adds a chemical structure called the 5' cap to the beginning of the mRNA strand shortly after transcription from DNA. This capping process involves attaching a modified guanine nucleotide to the mRNA through a unique 5’-5’ linkage.

The primary product types of mRNA capping enzymes are recombinant and natural enzymes. Recombinant mRNA capping enzymes are genetically engineered proteins that specifically catalyze the capping of RNA molecules. These enzymes are used in research and development, therapeutics, diagnostics, and other applications. Key end-users include pharmaceutical and biotechnology companies, research institutions, and contract manufacturing organizations (CMOs).

The messenger ribonucleic acid (mRNA) capping enzyme market research report is one of a series of new reports that provides messenger ribonucleic acid (mRNA) capping enzyme market statistics, including messenger ribonucleic acid (mRNA) capping enzyme industry global market size, regional shares, competitors with a messenger ribonucleic acid (mRNA) capping enzyme market share, detailed messenger ribonucleic acid (mRNA) capping enzyme market segments, market trends and opportunities, and any further data you may need to thrive in the messenger ribonucleic acid (mRNA) capping enzyme industry. This messenger ribonucleic acid (mRNA) capping enzyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The messenger ribonucleic acid (mRNA) capping enzyme market consists of sales of inorganic pyrophosphatase, murine RNase inhibitor, and polymerase chain reaction enzymes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.